Pfizer and BioNTech to Potentially Supply the EU with 200 Million Doses of mRNA-based Vaccine Candidate Against SARS-CoV-2

The proposed agreement is intended to provide a supply of 200 million doses and an option to purchase additional 100 million doses, with deliveries starting by the end of 2020, subject to regulatory approval The vaccine supply for the EU would be produced by BioNTech’s manufacturing sites in Germany […]

Click here to view original web page at www.pfizer.com

Earlier today, we announced a proposed agreement with @EU_Commission to provide a supply of 200 MM doses and an option to purchase additional 100 MM doses of our #COVID19 vaccine candidate, subject to regulatory approval.

— Pfizer Inc. (@pfizer) September 9, 2020

View this post on Instagram

Our long heritage 📘 Of producing life-changing #vaccines 👩🏽‍🔬 Is built on outstanding #innovation 💡 Not only in #research & development 🧪 But also in #manufacturing 📦 . . Visit pfizer.com to see how we're leveraging this deep knowledge to support the global supply of a potential #COVID19 vaccine. . . #Coronavirus #Pandemic #Outbreak #Vaccines #Science #Manufacturing #Technology #SupplyChain #STEM #EssentialWorkers #PfizerProud

A post shared by Pfizer Inc. (@pfizerinc) on Jul 20, 2020 at 6:51am PDT